Premium
CYP2D6 poor metabolizers in depressed women of Mexican origin
Author(s) -
Flores D. L.,
Flockhart D.,
Licinio J.
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.11.153
Subject(s) - cyp2d6 , genotyping , pharmacogenetics , desipramine , medicine , pharmacology , placebo , adverse effect , population , clinical significance , genotype , biology , genetics , alternative medicine , environmental health , antidepressant , cytochrome p450 , metabolism , pathology , hippocampus , gene
Purpose Pharmacogenetic information regarding the Mexican‐American population is sparse. It has been suggested that fewer Mexican‐Americans are CYP2D6 poor metabolizers than Anglos. While some studies have reported that U.S. Hispanics are more sensitive to drugs metabolized by CYP2D6 others have not shown differences. Our ongoing study investigates the pharmacogenetics of desipramine or fluoxetine in the in the Los Angeles Mexican‐origin population. Methods: Subanalysis of a prospective, double‐blind, placebo‐controlled study. Results: We describe two Mexican‐American women who were found to have elevated levels of desipramine and severe side effects after taking a minimal dose for two weeks. CYP2D6 genotyping indicated both women to have the mutant allele * 4/*4 which has been found in poor metabolizers. Conclusions: CYP2D6 genotyping is of considerable public health relevance. This should become a routine laboratory exam for patients who are treated with medications that are metabolized by this enzyme, including minorities whose adverse responses are at times inappropriately attributed to cultural factors. Clinical Pharmacology & Therapeutics (2004) 75 , P41–P41; doi: 10.1016/j.clpt.2003.11.153